XELOX (capecitabine plus oxaliplatin) plus bevacizumab (anti-VEGF-A antibody) with or without adoptive cell immunotherapy in the treatment of patients with previously untreated metastatic colorectal cancer: a multicenter, open-label, randomized, controlled, phase 3 trial [0.03%]
卡培他滨和奥沙利铂联合贝伐珠单抗（血管生成抑制剂）并有或没有过继性细胞免疫治疗新诊断的转移性结直肠癌患者：一项多中心、开放标签、随机对照III期临床试验
Qiu-Zhong Pan,Jing-Jing Zhao,Liang Liu et al.
Qiu-Zhong Pan et al.
Fluoropyrimidine-based combination chemotherapy plus targeted therapy is the standard initial treatment for unresectable metastatic colorectal cancer (mCRC), but the prognosis remains poor. This phase 3 trial (ClinicalTrials.gov: NCT0395015...
Optimizing oncolytic virus design: a "Swiss army knife" approach to create a systemically delivered therapeutic [0.03%]
优化溶瘤病毒设计：创建可全身递送的治疗性“瑞士军刀”系统
Carolina S Ilkow,John Cameron Bell
Carolina S Ilkow
Adeno-associated virus as a delivery vector for gene therapy of human diseases [0.03%]
腺相关病毒作为人类疾病基因治疗的载体病毒
Jiang-Hui Wang,Dominic J Gessler,Wei Zhan et al.
Jiang-Hui Wang et al.
Adeno-associated virus (AAV) has emerged as a pivotal delivery tool in clinical gene therapy owing to its minimal pathogenicity and ability to establish long-term gene expression in different tissues. Recombinant AAV (rAAV) has been enginee...
Macrocyclic peptides: up-and-coming weapons to combat antimicrobial resistance [0.03%]
大环肽：对抗抗生素抗性的新兴武器
Wen-Jing Wang,Xiang-Min Dong,Guo-Bo Li
Wen-Jing Wang
Mex-3 RNA binding family member A (MEX3A)/circMPP6 complex promotes colorectal cancer progression by inhibiting autophagy [0.03%]
Mex-3家族RNA结合成员A（MEX3A）/环状MPP6复合体通过抑制自噬促进结直肠癌进展
Ri-Xin Chen,Shui-Dan Xu,Min-Hua Deng et al.
Ri-Xin Chen et al.
RNA-binding proteins (RBPs)-RNA networks have contributed to cancer development. Circular RNAs (circRNAs) are considered as protein recruiters; nevertheless, the patterns of circRNA-protein interactions in colorectal cancer (CRC) are still ...
Messing with cancer therapy: how the melanoma phenotype predicts checkpoint inhibitor response [0.03%]
玩弄癌症治疗：如何通过黑色素瘤表型预测检查点抑制剂的反应
Svenja Meierjohann,Corine Bertolotto
Svenja Meierjohann
The two sides of chromosomal instability: drivers and brakes in cancer [0.03%]
染色体不稳定的两面：癌症中的驱动因素与制动因素
Rendy Hosea,Sharon Hillary,Sumera Naqvi et al.
Rendy Hosea et al.
Chromosomal instability (CIN) is a hallmark of cancer and is associated with tumor cell malignancy. CIN triggers a chain reaction in cells leading to chromosomal abnormalities, including deviations from the normal chromosome number or struc...
RNA modifications in cellular metabolism: implications for metabolism-targeted therapy and immunotherapy [0.03%]
细胞代谢中的RNA修饰：对代谢靶向疗法和免疫疗法的影响
Wei-Wei Liu,Si-Qing Zheng,Tian Li et al.
Wei-Wei Liu et al.
Cellular metabolism is an intricate network satisfying bioenergetic and biosynthesis requirements of cells. Relevant studies have been constantly making inroads in our understanding of pathophysiology, and inspiring development of therapeut...
Rapid development of double-hit mRNA antibody cocktail against orthopoxviruses [0.03%]
针对正痘病毒的双靶点mRNA抗体鸡尾酒疗法的快速开发
Hang Chi,Suo-Qun Zhao,Ru-Yi Chen et al.
Hang Chi et al.
The Orthopoxvirus genus, especially variola virus (VARV), monkeypox virus (MPXV), remains a significant public health threat worldwide. The development of therapeutic antibodies against orthopoxviruses is largely hampered by the high cost o...
First-line camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and chemotherapy for advanced gastric cancer (SPACE): a phase 1 study [0.03%]
斯鲁利单抗联合阿帕替尼和化疗一线治疗晚期胃癌的一项I期研究(SPACE研究)
Xiaofeng Chen,Hao Xu,Xiaobing Chen et al.
Xiaofeng Chen et al.
Patients with advanced gastric cancer typically face a grim prognosis. This phase 1a (dose escalation) and phase 1b (dose expansion) study investigated safety and efficacy of first-line camrelizumab plus apatinib and chemotherapy for advanc...